Interview with Israel Garcia Crespo, General Manager, Almirall Mexico
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Address: Periferico Sur 3325 Piso 1, Col. San Jeronimo Lidice, Mexico D.F.
,Mexico
Tel: +52 5 559 998 600
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company with headquarters in Spain, based on innovation and committed to health, and develops, manufactures and commercializes its own Research & Development driven licensed drugs, with the aim of improving health and welfare of people. Currently, our drugs are marketed in over 70 countries including the USA and Japan, either through our own subsidiaries or through marketing agreements with renowned pharmaceutical companies. Almirall has 11 subsidiaries in Europe, including Spain, Germany, Austria, Belgium, France, Italy, Poland, Portugal, United Kingdom, Ireland and Switzerland and Mexico. Almirall S.A. de C.V.- the company’s only Latin American presence- began operating in 2000 with the aim of consolidating the company’s international expansion and entering placing its main strategic products into the Mexican market specifically.
Almirall S.A. de C.V. currently has 9 innovative products in the Mexican market in fields ranging from Dermatology to Oncology, which provide solutions to Mexican society in improving their quality of life and health.
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Organon’s recently-appointed LAMEX Cluster Head Julio Conejero lays out how Organon is committed to improving women’s health and addressing unmet needs through its portfolio. This mission aligns with the rise…
The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could…
Hernán Porcile, General Manager of Takeda Mexico, discusses the company’s innovative therapies, regulatory strategies, and the integration of ” “Takeda-ism” within the Mexican cultural context. He emphasizes Takeda’s commitment to…
Oswaldo Bernal explains how Mexico is BMS’ top-performing market in Latin America (outside of Brazil) and plays a significant role in the company’s global growth strategy. He also discusses how…
The French Chamber of Commerce in Mexico (CCI France Mexico) has been helping French companies such as Sanofi, Servier and Pierre Fabre establish themselves in Mexico for 140 years. General…
Jorge Luis Caridad, managing director of Johnson & Johnson Innovative Medicine, Mexico, explores his 18-year journey within the company, emphasizing his alignment with J&J’s values and its mission to transform…
Founded in 1943, Mexican drugmaker Silanes has built a strong presence across multiple therapeutic areas, namely diabetes and cardiovascular, while expanding into others. The company’s director of pharma and biologics,…
Francisco Chavez from Thermo Fisher Scientific explains the company’s global mission to advance science and healthcare, with a particular focus on Latin America. Chavez highlights Thermo Fisher’s significant investment in…
Carlos Hernandez and Daniel Kilian discuss OECHSLER’s decision to diversify into the medical device industry, leveraging the company’s expertise in automotive manufacturing; how Mexico has become a crucial strategic hub…
Valney Suzuki highlights his focus on expanding access to Novo Nordisk’s innovations in Mexico, especially for vulnerable populations; the importance of ethical usage of the company’s groundbreaking semaglutide-based treatments for…
Pedro Casas Alatriste of AmCham Mexico delves into the chamber’s efforts to enhance U.S.-Mexico trade relations, support key industries, and promote sustainable growth amid Mexico’s political transition. We are…
David López García, a pharma industry executive and rare disease expert, discusses the challenges and advancements in treating rare diseases in Mexico. He highlights the importance of public-private partnerships and…
See our Cookie Privacy Policy Here
